Hearing profile in hepatitis C virus patients under dual treatment with interferon and ribavirin (original) (raw)
Related papers
The Egyptian Journal of Otolaryngology, 2015
This study aimed to study the effect of combined pegylated interferon and ribavirin audiometry (conventional and high frequency) and distortion product otoacoustic emissions (DPOAEs in the form of a DP-gram) immediately before therapy and at the end of the 12th and 24th weeks. Vestibulocochlear adverse effects including hearing loss, tinnitus, vertigo, and otalgia were also considered. and 24th weeks with those at the onset of the study. The elevations were mostly at higher F 2 frequencies on comparing both amplitudes and signal to noise ratios at the 12th and 24th weeks with F 2 frequencies. Otologic from 0 to 31.1% by the end of the study. patients, highlighting the importance of prompt monitoring of auditory functions in these patients. audiometry, distortion product otoacoustic emissions, hepatitis, interferon, ribavirin
Effect of interferon treatment on hearing of patients with chronic Hepatitis C
Saudi Journal of Gastroenterology, 2011
Background/Aim: Some reports in the literature have linked interferon therapy for the treatment of hepatitis C (HCV) with hearing loss. The aim of this study has been to examine the effects of interferon therapy on hearing of patients treated for HCV. Patients and Methods: Patients were recruited according to preset inclusion criteria from two centers. All patients received standard dose pegylated interferon (PEG-IFN α-2b or α-2a) plus ribavirin (RBV). All patients had pure-tone audiometry (PTA), tympanogram and distortionproduct otoacoustic emission (DPOAE) before treatment, three months after initiation of treatment, and three months after completion of treatment. Results: Twenty one patients were prospectively recruited. The mean age was 45.7 years. The male to female ratio was 1.1:1. The mean PTA was 15.9 ± 5.3 before treatment, 17.4 ± 6.1 during treatment and 16.5 ± 5.1 after treatment. The differences between pre and mid, pre and post, as well as mid and post were not significantly different (P>0.05) in all audiological assessments. Conclusions: Our results indicate that PEG-IFN\RBV therapy does not have any impact on the hearing thresholds of patients with HCV.
Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
Journal of Otology, 2018
Objective Evaluating the auditory function in patients with chronic hepatitis C treated with sofosbuvir and ribavirin. Methods This study involved 80 patients with chronic hepatitis C who agreed to receive sofosbuvir and ribavirin. All participants were subjected to baseline otological and audiological assessment just before treatment. The audiological assessment included standard pure tone audiometry, extended high-frequency audiometry, immitancemetry and otoacoustic emissions (OAEs) (transient and distortion product). According to baseline hearing threshold measurements, the study population was divided into 2 groups. Group 1 included 42 patients with normal hearing sensitivity (250–8000 Hz), and Group 2 included 38 patients with sensorineural hearing loss. After 24 weeks of therapy, otological and audiological assessments were repeated and compared between the two groups and before and after therapy. Results Post-treatment hearing threshold evaluation showed no significant differ...
The Brazilian Journal of Infectious Diseases, 2011
Sudden hearing loss is defi ned as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with signifi cant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians should be aware of the possible ototoxic effects of peginterferon and ribavirin combination therapy requiring appropriate surveillance.
Auris Nasus Larynx, 2003
To investigate the possible ototoxic effects of recombinant interferon alpha (IFN alpha) on patients with hepatitis B. Patients and method: Twenty-seven adult patients (14 male, 13 female) with chronic hepatitis B who were administered recombinant IFN alpha treatment were selected for this study. These patients were treated with a dose of 10 MU three times per week during 8 Á/ 12 months (average follow-up period was 11.2 month). The mean hearing thresholds at seven frequencies (250 Á/8000 Hz) were determined the day before therapy, after 1st, 7th and 21st day, and 1 month after termination of treatment. Results: Hearing loss was detected in nine of 27 patients on the 7th day and the degree of hearing loss increased until 21st day of treatment. It was not exceeded 20 dB for any frequency with continued IFN therapy. The hearing loss completely recovered 1 month after the cessation of the IFN alpha. When hearing thresholds values of the day before therapy, 1st day and 1 month after termination of treatment were compared with values of 7th and 21st days, a statistically significant difference was detected (P B/0.001). But there was no significant difference between the hearing thresholds values of the day before therapy, 1st day and 1 month after termination of the treatment (P /0.05). Conclusion: IFN alpha administration in patients with hepatitis B may cause mild reversible sensorineural hearing loss. #
Audiological Findings in Autoimmune Hepatitis: Hearing Loss at High Frequencies
Gazi Medical Journal, 2017
Objectives: In this study we aimed to examine the audiological findings in autoimmune hepatitis (AIH). Patients and Methods: Nine patients with the diagnosis of AIH were included in the study. Eighteen healthy age and sex matching volunteers constituted the control group. All the subjects underwent audiologic evaluation with pure tone and speech audiometry. Results: Pure tone air conduction threshold averages for right ears in study and control group were 10.14 ± 4.70 and 6.73 ± 1.43 dB, respectively (p=0.022). Pure tone air conduction threshold averages for left ears in study and control group were 10.42 ± 4.84 and 6.66 ± 1.35 dB, respectively (p=0.018). There was significant decline at high frequencies (4000, 6000 and 8000 Hz) in AIH group compared to healthy controls (p<0.05). Speech reception thresholds and speech discrimination percentages were also significantly decreased in AIH (p<0.05). Conclusion: In conclusion, this is the first study in the literature showing the presence of hearing loss in AIH. However further studies with larger groups and including other assessment tools such as OAE are needed.
Study of Prevalence and Pattern of Hearing Loss in Patients of Hepatitis B
International Journal of Medical and Biomedical Studies, 2019
Hepatitis B has been documented to cause various extra hepatic manifestations along with known hepatic complications. It has been reported that hepatitis-B patients are more susceptible to inner ear damage and hearing loss. The aim of this study is to evaluate hearing loss among patients of hepatitis B {all 6 categories Hepatitis B infection: chronic Hepatitis B infection , hepatitis B cirrhosis ,Hepatitis B virus carriers , occult chronic Hepatitis B and Hepatitis B infection with poly arthritis nodosa, hepato cellular carcinoma with hepatitis B}compared with healthy subjects. METHOD: In this case control study 100 Hepatitis B positive patients and 100 age and gender-matched healthy individuals were included over the period of 5 years. All of them were known cases of chronic hepatitis B positive for HBsAg at least for 18 months. All patients were aged 18 to 50 years to exclude presence of presbycusis. After base line investigations, they were subjected for all cases and cont...
Viral infections in sudden hearing loss. Do we have enough evidence?
Kathmandu University medical journal (KUMJ)
The aetiology of sudden deafness remains unknown even though some evidences suggest that it could be viral in origin. This study aimed to find out the relationship between viral infections and sudden sensorineural hearing loss. 32 patients presenting with sudden deafness and 10 healthy controls were included in the study. IgM antibodies to varicella zoster virus, measles, cytomegalovirus and herpes simplex virus were detected using micro ELISA. Overall, 7(21.8%) patients showed seropositivity to one or more viruses. Virus specific IgM antibodies against measles and varicella zoster could be demonstrated in 4 (12.5%) and 3 (9.4%) patients respectively. None of the samples were found to be positive for herpes simplex virus (HSV) and human cytomegalovirus (HCMV) specific IgM antibodies. Controls were negative for all the viruses tested. The difference in seropositivity between the patient and control group was not statistically significant (p>0.05). Thus, this study suggests that su...